Encapsulated FMT

Phase 3Small molecule

KKing's College London

Encapsulated FMT is one of 36 small molecule programs targeting Cirrhosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CirrhosisActive, not recruiting

CirrhosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

9 2

Encapsulated FMT

KKing's College London

Phase 3

1 3

Crestor

AstraZeneca

Preclinical

2 4

Thalomid

Bristol-Myers Squibb

Preclinical

1 5

Farxiga

AstraZeneca

Preclinical

1 6

Dobutrex

Eli Lilly

Preclinical

1 7

HEPCLUDEX

Gilead

Preclinical

1 8

Cipro

Bayer

Preclinical

1 9

Revia

Teva

Preclinical

1 10

Coreg

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Cirrhosis

NCT06461208

Clinical

Trials by Indication[1]

Cirrhosis1 trial

A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis

Recruiting·KKing's College London·Phase 3·NCT06461208·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Encapsulated FMT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Encapsulated FMT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Encapsulated FMT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — King's College London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKing's College London

Encapsulated FMT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News